Loading…
Loading…
OXBOF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for OXBOF and 80,000+ other tickers.
See exactly how OXBOF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for OXBOF and 80,000+ other tickers.
Headquartered in Oxford, United Kingdom, and established in 2007, Oxford BioDynamics Plc operates as a biotechnology enterprise. The company's primary focus lies in the discovery and development of biomarkers for the pharmaceutical and biotechnology industries, serving both domestic and international markets, with a significant presence in the United States. Central to its operations is EpiSwitch, a proprietary technology platform. This platform facilitates the identification, evaluation, validation, and continuous monitoring of epigenetic biomarkers, specifically referred to as chromosome…
Oxford BioDynamics PLC (AIM:OBD, OTC:OXBOF) shares surged 33% on Wednesday after the company announced it had developed a highly accurate blood test to diagnose Chronic Fatigue Syndrome, a condition that has long lacked a reliable means of detection. The AIM-listed diagnostics firm said the test, created with researchers at the University of East Anglia, achieved 96% accuracy in identifying the condition, also known as Myalgic Encephalomyelitis, or ME.
Oxford BioDynamics PLC (AIM:OBD, OTC:OXBOF) has developed what it calls a “first-in-class” blood test to diagnose Chronic Fatigue Syndrome, a breakthrough that could help end years of uncertainty for patients struggling to obtain a clear diagnosis. The AIM-listed diagnostics company said the test, created with researchers at the University of East Anglia, achieved 96% accuracy in identifying the condition, also known as Myalgic Encephalomyelitis, or ME.
Oxford BioDynamics PLC (AIM:OBD, OTC:OXBOF) shares strengthened on Thursday, after the health diagnostics company reported that its EpiSwitch CiRT blood test was shown to influence clinical decisions in more than 60% of cases. The finding came via interim results from the ongoing PROWES study.
Oxford BioDynamics PLC (AIM:OBD, OTC:OXBOF) executive chairman Iain Ross talked with Proactive about the company's new partnership with Google Cloud, a move he described as a major growth catalyst for both Oxford BioDynamics and the field of 3D genomics. Ross outlined how the deal will support the global scaling of the company's EpiSwitch platform by making it cloud native, allowing faster deployment, greater accessibility, and continuous updates.
Oxford BioDynamics PLC (AIM:OBD) shares soared in early deals, as it unveiled a new collaboration with Google Cloud. In the project, they plan to develop and deploy Oxford BioDynamics' EpiSwitch analytical framework on the cloud.